Want to see ISPC full AI Analyst Report?
Top Page
iSpecimen
(NASDAQ:ISPC)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-6.25% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by very weak fundamentals—sharp revenue decline, negative gross profit, and ongoing cash burn—alongside a bearish technical trend (price below key moving averages with negative MACD). Corporate events provide some offset via added capital and strategic AI-focused assets, but dilution and execution risk limit the uplift, and valuation is constrained by negative earnings.
Positive Factors
Low Leverage
Modest leverage reduces immediate balance-sheet pressure and limits interest-related strain compared with a highly indebted business. This gives iSpecimen some financial flexibility to pursue operations and technology investments, although continuing losses remain a significant constraint on that flexibility.
Negative Factors
Sharp Revenue and Margin Deterioration
The combination of collapsing revenue and negative gross profit indicates that the core service economics are currently not covering delivery costs. Sustained operating losses reduce the company’s ability to reinvest, scale its marketplace, or withstand further weakness without additional external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Modest leverage reduces immediate balance-sheet pressure and limits interest-related strain compared with a highly indebted business. This gives iSpecimen some financial flexibility to pursue operations and technology investments, although continuing losses remain a significant constraint on that flexibility.
Read all positive factors
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.88M
Dividend YieldN/A
Average Volume (3M)569.05K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue Growth-92.11%
EPS Growth86.78%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,518,590
10 Day Avg. Volume770,562
30 Day Avg. Volume569,046
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iSpecimen Business Overview & Revenue Model
Company Description
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate a...
How the Company Makes Money
iSpecimen primarily makes money by facilitating transactions between research customers (such as pharmaceutical companies, biotechnology companies, and academic or government laboratories) and a network of specimen suppliers (such as hospitals, pa...
iSpecimen Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 466.30K | 1.93M | 9.29M | 9.93M | 10.40M | 11.14M |
| Gross Profit | -706.30K | 24.11K | 3.99M | 5.11M | 5.65M | 5.89M |
| EBITDA | -10.25M | -8.75M | -10.38M | -8.80M | -8.80M | -5.86M |
| Net Income | -11.42M | -10.49M | -12.50M | -11.10M | -10.25M | -8.96M |
Balance Sheet | ||||||
| Total Assets | 7.39M | 9.53M | 9.35M | 15.82M | 24.62M | 35.72M |
| Cash, Cash Equivalents and Short-Term Investments | 4.41M | 6.88M | 1.88M | 5.01M | 15.31M | 27.74M |
| Total Debt | 240.90K | 268.80K | 312.17K | 196.24K | 185.85K | 3.42M |
| Total Liabilities | 5.66M | 6.44M | 6.04M | 6.08M | 4.31M | 5.93M |
| Stockholders Equity | 1.74M | 3.09M | 3.31M | 9.74M | 20.31M | 29.79M |
Cash Flow | ||||||
| Free Cash Flow | -8.00M | -4.24M | -8.30M | -10.55M | -9.01M | -11.71M |
| Operating Cash Flow | -7.00M | -4.24M | -8.26M | -5.81M | -5.82M | -10.67M |
| Investing Cash Flow | -1.00M | -1.00M | 1.98M | -7.23M | -3.19M | -1.04M |
| Financing Cash Flow | 12.53M | 10.24M | 5.82M | 70.89K | -3.42M | 38.75M |
iSpecimen Technical Analysis
Negative
1.60
Price Trends
2.12
Negative
3.05
Negative
7.77
Negative
Market Momentum
-0.20
Positive
34.07
Neutral
40.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 1.6 is below the 20-day moving average (MA) of 1.89, below the 50-day MA of 2.12, and below the 200-day MA of 7.77, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 34.07 is Neutral, neither overbought nor oversold. The STOCH value of 40.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.
iSpecimen Risk Analysis
iSpecimen disclosed 74 risk factors in its most recent earnings report. iSpecimen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
iSpecimen Peers Comparison
UnderperformOutperform
Sector (51)
ISPC
iSpecimen
1.54
-28.34
-94.85%
INBS
Intelligent Bio Solutions
2.23
-14.22
-86.44%
BGLC
BioNexus Gene Lab Corp
1.45
-3.51
-70.77%
BIAF
bioAffinity Technologies, Inc.
15.27
-94.98
-86.15%
iSpecimen Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
iSpecimen to Acquire Foldlab AI Disease Analytics
Positive
Sep 4, 2026
On September 4, 2026, iSpecimen Inc. agreed to acquire AI software, models, source code, data rights and related IP from Foldlab AI Ltd. for a total consideration of $4.5 million, split between $2 million in cash and $2.5 million in common stock. ...
Business Operations and StrategyRegulatory Filings and Compliance
iSpecimen Engages IR Agency for Investor Marketing
Neutral
Aug 14, 2026
On August 12, 2026, iSpecimen Inc. entered into a three-month Consulting Agreement with IR Agency LLC to provide non-exclusive marketing and advertising services aimed at communicating information about the company to the financial community. The ...
Business Operations and StrategyFinancial DisclosuresLegal Proceedings
iSpecimen Settles Arbitration and Terminates WestPark Agreements
Neutral
Aug 11, 2026
On August 6, 2026, iSpecimen entered into a Settlement Agreement and Mutual Release with WestPark Capital to resolve an arbitration stemming from investment banking engagement agreements related to WestPark’s role as underwriter for iSpecime...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
iSpecimen Completes $5 Million Public Offering
Positive
Aug 7, 2026
On August 5, 2026, iSpecimen Inc. entered into agreements with E.F. Hutton Co. and participating investors for a “reasonable best efforts” public offering comprising 996,231 shares of common stock and pre-funded warrants to purchase u...
Business Operations and StrategyProduct-Related Announcements
iSpecimen advances digital transformation with Milestone 3 completion
Positive
Jul 15, 2026
On July 9, 2026, iSpecimen Inc. completed Milestone 3 in its digital transformation program powered by SalesStack Solutions, triggering a $700,000 payment under its software purchase and services agreement. The new milestone adds marketplace featu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.